European Archives - Page 63 of 1607 - European Medical Journal

Lettuce

Cyclosporiasis outbreak drives fresh produce concerns

A food poisoning outbreak linked to lettuce is driving concerns among consumers.

Delgocitinib Cream Showed Dose Dependent Benefits in Atopic Dermatitis

An 8 week Phase IIb trial found that delgocitinib cream produced dose dependent improvements in adults with mild to severe atopic dermatitis while maintaining a favourable safety profile compared with cream vehicle.

Sex Differences in Cancer Proteome Revealed Across Tumour Types

Sex differences in cancer proteome patterns were identified across eight tumour types, with the greatest variation seen in lung adenocarcinoma.

Everolimus Linked to Lower Cancer Risk After Liver Transplant

Patients who initiated everolimus after liver transplantation had a lower incidence of new cancers in a nationwide French analysis using emulated clinical trials.

EU Approves Novel Fibre to Help Prevent Weight Gain

The EU has approved the novel dietary fibre IPE, developed by Imperial College London researchers, to help prevent weight gain by increasing feelings of fullness.

Pancreatic Acinar Cell Carcinoma Imaging May Predict Recurrence

Pancreatic acinar cell carcinoma imaging may help distinguish this rare tumour from other pancreatic cancers and identify patients at higher risk of recurrence after surgery.

Balancing speed and stewardship in AMR

In the UK, Fetcroja® (Cefiderocol) is indicated for the treatment of infections due to aerobic Gram-negative organisms in adults with…

EAN 2026 Interview: Kailash Bhatia

In my view, the biggest advance that has changed lives is functional neurosurgery; for example, deep brain stimulation surgery and…

Beyond the FTD Umbrella: Time for a Biological Definition?

The reader will permit the author to introduce this letter with a digression: to mark the release of a Hollywood film based on Homer’s…

Rising bar chart

AstraZeneca up 6% in Q2 as oncology drives growth

AstraZeneca maintained revenue growth in the second quarter of 2026 as demand for its oncology medicines grew.